false 0000922247 0000922247 2024-10-04 2024-10-04 0000922247 ctdh:CommonStockParValue0001PerShareCustomMember 2024-10-04 2024-10-04 0000922247 ctdh:WarrantsToPurchaseCommonStockCustomMember 2024-10-04 2024-10-04

 

 

 

 

Date of Report (Date of earliest event reported)

 

(Exact name of registrant as specified in its charter)

 

 

 

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On October 4, 2024, Cyclo Therapeutics, Inc. (the "Company”) received two letters from The Nasdaq Stock Market ("Nasdaq”) stating that the Company was not in compliance with (1) Nasdaq Listing Rule 5550(a)(2) for failing to maintain a closing bid price of no less than $1.00 per share for 30 consecutive trading days, (2) Nasdaq Listing Rule 5550(b)(1) because the stockholders’ equity of the Company was below the minimum requirement of $2.5 million, (3) Nasdaq Listing Rule 5550(b)(2) for failing to maintain a minimum Market Value of Listed Securities of $35 million, and (4) Nasdaq Listing Rule 5550(b)(3) for failing to maintain net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years.

 

Pursuant to the Nasdaq Listing Rules, the Company has 180 calendar days (until April 2, 2025) to regain compliance with the Nasdaq Listing Rules.

 

In the event the Company does not regain compliance with Nasdaq Listing Rule 5550(a)(2) prior to the expiration of the compliance period, the Company may be granted an additional 180 calendar days to regain compliance, subject to certain conditions. In the event the Company does not regain compliance with Nasdaq Listing Rule 5550(b)(2) prior to the expiration of the compliance period, the Company will receive written notification from Nasdaq that its securities are subject to delisting.

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.